APA
FATE icon

American Portfolios Advisors’s Fate Therapeutics FATE Stock Holding History

American Portfolios Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$66.9K Buy
2,985
+390
+15% +$11.3K ﹤0.01% 1553
2022
Q2 		$64.3K Buy
2,595
+870
+50% +$24K ﹤0.01% 1628
2022
Q1 		$66.9K Buy
1,725
+1,145
+197% +$44.3K ﹤0.01% 1739
2021
Q4 		$33.9K Sell
580
-75
-11% -$4.25K ﹤0.01% 2068
2021
Q3 		$38.8K Buy
655
+580
+773% +$45.5K ﹤0.01% 1915
2021
Q2 		$6.51K Buy
+75
New +$6.04K ﹤0.01% 2713
2020
Q4 		– Sell
-1,400
Closed -$56K – 3015
2020
Q3 		$56K Buy
1,400
+250
+22% +$8.73K ﹤0.01% 1282
2020
Q2 		$39.5K Buy
+1,150
New +$34.3K ﹤0.01% 1372

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

American Portfolios Advisors's FATE Position: Q3 2022 in Review

American Portfolios Advisors increased its Fate Therapeutics (FATE) stake by 15% in Q3 2022, buying an estimated $11.3K and bringing the position to 2,985 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.

American Portfolios Advisors first reported a position in FATE in Q2 2020 and has held it in 8 quarters since. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • American Portfolios Advisors held 2,985 shares of Fate Therapeutics worth $66.9K as of Q3 2022.
  • American Portfolios Advisors bought 390 Fate Therapeutics shares in Q3 2022, an estimated $11.3K.
  • Fate Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #1553 holding.
  • American Portfolios Advisors first reported a position in Fate Therapeutics in Q2 2020 and has held it in 8 quarters since.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.